{"nctId":"NCT02373813","briefTitle":"Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission","startDateStruct":{"date":"2015-02-20","type":"ACTUAL"},"conditions":["Rheumatoid Arthritis"],"count":371,"armGroups":[{"label":"Open Label Run-In: Etanercept plus Methotrexate","type":"EXPERIMENTAL","interventionNames":["Drug: etanercept pre-filled syringe subcutaneous injection","Drug: Oral methotrexate","Dietary Supplement: Folic acid (non-investigational product)"]},{"label":"Double-Blind Treatment: Methotrexate Monotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: etanercept pre-filled syringe subcutaneous injection","Drug: Oral methotrexate","Drug: Placebo for etanercept subcutaneous injection","Dietary Supplement: Folic acid (non-investigational product)"]},{"label":"Double-Blind Treatment: Etanercept Monotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: etanercept pre-filled syringe subcutaneous injection","Drug: Oral methotrexate","Drug: Placebo for methotrexate","Dietary Supplement: Folic acid (non-investigational product)"]},{"label":"Double-Blind Treatment: Etanercept plus Methotrexate","type":"EXPERIMENTAL","interventionNames":["Drug: etanercept pre-filled syringe subcutaneous injection","Drug: Oral methotrexate","Dietary Supplement: Folic acid (non-investigational product)"]}],"interventions":[{"name":"etanercept pre-filled syringe subcutaneous injection","otherNames":["Enbrel","AMG916"]},{"name":"Oral methotrexate","otherNames":[]},{"name":"Placebo for etanercept subcutaneous injection","otherNames":[]},{"name":"Placebo for methotrexate","otherNames":[]},{"name":"Folic acid (non-investigational product)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria (Part 1, Run-In Period):\n\n* Subjects must be adults with a history of moderate to severe rheumatoid arthritis;\n* Subjects must be in very good rheumatoid arthritis disease control for ≥ 6 months and be in remission as defined by a Simplified Disease Activity Index ≤ 3.3 at screening and at the end of the run-in period.\n* Subjects must be on etanercept 50 mg per week plus methotrexate therapy for ≥ 6 months prior to the start of the run-in period. The methotrexate dose must be 10 to 25 mg per week for ≥ 6 months prior to the start of the run-in period and the dose must be stable for ≥ 8 weeks prior to the start of the run-in period.\n* Subject has no known history of active tuberculosis, and has a negative test for tuberculosis during screening.\n\nExclusion Criteria (Part 1, Run-In Period):\n\n* Subject has used biologic disease modifying antirheumatic drug other than etanercept OR has used an oral janus kinase inhibitor ≤ 6 months prior to run-in visit 1\n* Subject has any active infection (including chronic or localized infections) for which anti-infectives were indicated within 4 weeks prior to run-in visit 1.\n* Subject has known alcohol addiction or dependency or uses alcohol daily.\n* Subject has one or more significant concurrent medical conditions per investigator judgment, including the following:\n\n  * poorly controlled diabetes\n  * chronic kidney disease stage IIIb, IV, or V\n  * symptomatic heart failure (New York Heart Association class II, III, or IV)\n  * myocardial infarction or unstable angina pectoris within the past 12 months prior to randomization\n  * uncontrolled hypertension\n  * severe chronic pulmonary disease (eg, requiring oxygen therapy)\n  * multiple sclerosis or any other demyelinating disease\n  * major chronic inflammatory disease or connective tissue disease other than rheumatoid arthritis (eg, systemic lupus erythematosus with the exception of secondary Sjögren's syndrome)\n\nInclusion Criteria (Part 2, Treatment Period):\n\n* SDAI ≤ 3.3 at run-in visit 3\n* Subject if female and not at least 2 years postmenopausal or history of hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, has a negative urine pregnancy test at baseline (day 1).\n\nExclusion Criteria (Part 2, Treatment Period):\n\n* Any clinically significant change in the Part 1 eligibility criteria during the run-in period\n* SDAI \\> 3.3 and ≤ 11 on two consecutive visits at least two weeks apart OR SDAI \\> 3.3 and ≤ 11 on two or more separate visits OR SDAI \\> 11 at any time during the run-in period\n* Subject has a clinically significant laboratory abnormality during run-in period which in the opinion of the investigator poses a safety risk, will prevent the subject from completing the study, or will interfere with the interpretation of the study results during the run-in period.\n\nNOTE: Other inclusion/exclusion criteria may apply per protocol.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission (≤ 3.3) at Week 48: Etanercept Monotherapy vs. Methotrexate Monotherapy","description":"The SDAI is a composite score that is based on the number of tender and swollen joints using a 28-joint count, Physician's Global Assessment of Disease Activity using a visual analog scale (VAS) where 0=no activity at all and 100=worst activity imaginable, Patient's Global Assessment of Disease Activity using a VAS where 0=no arthritis activity at all and 100=worst arthritis activity imaginable, and C-reactive protein (CRP) in mg/dL. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. SDAI remission was defined as a score of ≤ 3.3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7","spread":null},{"groupId":"OG001","value":"49.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SDAI Remission (≤ 3.3) at Week 48: Etanercept and Methotrexate vs. Methotrexate Monotherapy","description":"The SDAI is a composite score that is based on the number of tender and swollen joints using a 28-joint count, Physician's Global Assessment of Disease Activity using a visual analog scale (VAS) where 0=no activity at all and 100=worst activity imaginable, Patient's Global Assessment of Disease Activity using a VAS where 0=no arthritis activity at all and 100=worst arthritis activity imaginable, and C-reactive protein (CRP) in mg/dL. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. SDAI remission was defined as a score of ≤ 3.3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7","spread":null},{"groupId":"OG001","value":"52.9","spread":null}]}]}]},{"type":"SECONDARY","title":"SDAI Score at All Measured Timepoints","description":"The SDAI is a composite score that is based on the number of tender and swollen joints using a 28-joint count, Physician's Global Assessment of Disease Activity using a visual analog scale (VAS) where 0=no activity at all and 100=worst activity imaginable, Patient's Global Assessment of Disease Activity using a VAS where 0=no arthritis activity at all and 100=worst arthritis activity imaginable, and C-reactive protein (CRP) in mg/dL. The SDAI score ranges from 0 to 86, with higher scores representing worse disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.29","spread":"0.10"},{"groupId":"OG001","value":"1.26","spread":"0.14"},{"groupId":"OG002","value":"1.18","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.01","spread":"1.01"},{"groupId":"OG001","value":"4.37","spread":"0.75"},{"groupId":"OG002","value":"4.39","spread":"1.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.61","spread":"0.98"},{"groupId":"OG001","value":"4.98","spread":"0.92"},{"groupId":"OG002","value":"3.28","spread":"0.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.03","spread":"0.62"},{"groupId":"OG001","value":"2.25","spread":"0.36"},{"groupId":"OG002","value":"2.41","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.41","spread":"0.40"},{"groupId":"OG001","value":"2.33","spread":"0.23"},{"groupId":"OG002","value":"2.86","spread":"0.92"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SDAI Score at All Measured Timepoints","description":"The SDAI is a composite score that is based on the number of tender and swollen joints using a 28-joint count, Physician's Global Assessment of Disease Activity using a visual analog scale (VAS) where 0=no activity at all and 100=worst activity imaginable, Patient's Global Assessment of Disease Activity using a VAS where 0=no arthritis activity at all and 100=worst arthritis activity imaginable, and C-reactive protein (CRP) in mg/dL. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. SDAI remission was defined as a score of ≤ 3.3. A negative change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.67","spread":"1.00"},{"groupId":"OG001","value":"3.14","spread":"0.75"},{"groupId":"OG002","value":"3.21","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.42","spread":"0.98"},{"groupId":"OG001","value":"3.78","spread":"0.91"},{"groupId":"OG002","value":"2.14","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.90","spread":"0.63"},{"groupId":"OG001","value":"1.06","spread":"0.38"},{"groupId":"OG002","value":"1.30","spread":"0.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.27","spread":"0.39"},{"groupId":"OG001","value":"1.16","spread":"0.24"},{"groupId":"OG002","value":"1.77","spread":"0.94"}]}]}]},{"type":"SECONDARY","title":"Disease Activity Score (28 Joint) Calculated Using the Erythrocyte Sedimentation Rate Formula (DAS28-ESR) at All Measured Timepoints","description":"The DAS28-ESR is a modified composite index that was designed to measure disease activity using the number of tender and swollen joints based upon a 28-joint count, ESR in mm/hr, and a 100 mm VAS measuring the participant's general health, from 0 (best) to 100 (worst). DAS28-ESR scores range from 0 to 9.4, where higher scores represent higher disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":"0.06"},{"groupId":"OG001","value":"1.88","spread":"0.07"},{"groupId":"OG002","value":"1.84","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":"0.14"},{"groupId":"OG001","value":"2.37","spread":"0.12"},{"groupId":"OG002","value":"2.32","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.41","spread":"0.13"},{"groupId":"OG001","value":"2.54","spread":"0.14"},{"groupId":"OG002","value":"2.17","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.32","spread":"0.11"},{"groupId":"OG001","value":"2.17","spread":"0.08"},{"groupId":"OG002","value":"2.16","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.22","spread":"0.10"},{"groupId":"OG001","value":"2.21","spread":"0.08"},{"groupId":"OG002","value":"2.11","spread":"0.13"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DAS28-ESR at All Measured Timepoints","description":"The DAS28-ESR is a modified composite index that was designed to measure disease activity using the number of tender and swollen joints based upon a 28-joint count, ESR in mm/hr, and a 100 mm VAS measuring the participant's general health, from 0 (best) to 100 (worst). DAS28-ESR scores range from 0 to 9.4, where higher scores represent higher disease activity. A negative change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"0.13"},{"groupId":"OG001","value":"0.50","spread":"0.10"},{"groupId":"OG002","value":"0.48","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"0.12"},{"groupId":"OG001","value":"0.69","spread":"0.13"},{"groupId":"OG002","value":"0.34","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"0.10"},{"groupId":"OG001","value":"0.31","spread":"0.08"},{"groupId":"OG002","value":"0.35","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.09"},{"groupId":"OG001","value":"0.34","spread":"0.07"},{"groupId":"OG002","value":"0.32","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Disease Activity Score (28 Joint) Using the C-Reactive Protein Formula (DAS28-CRP) at All Measured Timepoints","description":"The DAS28-CRP is a composite index that was designed to measure disease activity using the number of tender and swollen joints based upon a 28-joint count, CRP in mg/L, and a 100 mm VAS measuring the participant's general health from 0 (best) to 100 (worst). DAS28-CRP scores range from 0 to 9.4, where higher scores represent higher disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"0.03"},{"groupId":"OG001","value":"1.50","spread":"0.04"},{"groupId":"OG002","value":"1.54","spread":"0.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.36","spread":"0.13"},{"groupId":"OG001","value":"1.91","spread":"0.09"},{"groupId":"OG002","value":"1.94","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":"0.11"},{"groupId":"OG001","value":"2.00","spread":"0.11"},{"groupId":"OG002","value":"1.77","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.96","spread":"0.09"},{"groupId":"OG001","value":"1.67","spread":"0.06"},{"groupId":"OG002","value":"1.72","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.87","spread":"0.07"},{"groupId":"OG001","value":"1.67","spread":"0.05"},{"groupId":"OG002","value":"1.72","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DAS28-CRP at All Measured Timepoints","description":"The DAS28-CRP is a composite index that was designed to measure disease activity using the number of tender and swollen joints based upon a 28-joint count, CRP in mg/L, and a 100 mm VAS measuring the participant's general health from 0 (best) to 100 (worst). DAS28-CRP scores range from 0 to 9.4, where higher scores represent higher disease activity. A negative change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","spread":"0.12"},{"groupId":"OG001","value":"0.42","spread":"0.09"},{"groupId":"OG002","value":"0.41","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.11"},{"groupId":"OG001","value":"0.52","spread":"0.11"},{"groupId":"OG002","value":"0.25","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":"0.09"},{"groupId":"OG001","value":"0.18","spread":"0.06"},{"groupId":"OG002","value":"0.20","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.07"},{"groupId":"OG001","value":"0.19","spread":"0.04"},{"groupId":"OG002","value":"0.21","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Clinical Disease Activity Index (CDAI) at All Measured Timepoints","description":"The CDAI is a composite score that is based on the number of tender and swollen joints using a 28-joint count, Physician's Global Assessment of Disease Activity using a visual analog scale (VAS) where 0=no activity at all and 100=worst activity imaginable, and Patient's Global Assessment of Disease Activity using a VAS where 0=no arthritis activity at all and 100=worst arthritis activity imaginable. The CDAI score ranges from 0 to 76, where a higher score represents worse disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"0.10"},{"groupId":"OG001","value":"0.92","spread":"0.13"},{"groupId":"OG002","value":"0.71","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.42","spread":"0.98"},{"groupId":"OG001","value":"4.08","spread":"0.74"},{"groupId":"OG002","value":"3.95","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.07","spread":"0.95"},{"groupId":"OG001","value":"4.63","spread":"0.91"},{"groupId":"OG002","value":"2.35","spread":"0.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.60","spread":"0.63"},{"groupId":"OG001","value":"1.93","spread":"0.36"},{"groupId":"OG002","value":"2.04","spread":"0.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.06","spread":"0.38"},{"groupId":"OG001","value":"2.00","spread":"0.23"},{"groupId":"OG002","value":"2.61","spread":"0.91"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDAI at All Measured Timepoints","description":"The CDAI is a composite score that is based on the number of tender and swollen joints using a 28-joint count, Physician's Global Assessment of Disease Activity using a visual analog scale (VAS) where 0=no activity at all and 100=worst activity imaginable, and Patient's Global Assessment of Disease Activity using a VAS where 0=no arthritis activity at all and 100=worst arthritis activity imaginable. The CDAI score ranges from 0 to 76, where a higher score represents worse disease. A negative change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.39","spread":"0.97"},{"groupId":"OG001","value":"3.15","spread":"0.73"},{"groupId":"OG002","value":"3.24","spread":"1.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.09","spread":"0.95"},{"groupId":"OG001","value":"3.75","spread":"0.90"},{"groupId":"OG002","value":"1.70","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.69","spread":"0.63"},{"groupId":"OG001","value":"1.07","spread":"0.37"},{"groupId":"OG002","value":"1.41","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.17","spread":"0.37"},{"groupId":"OG001","value":"1.15","spread":"0.23"},{"groupId":"OG002","value":"2.00","spread":"0.92"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SDAI Remission (≤ 3.3) at All Measured Timepoints","description":"The SDAI is a composite score that is based on the number of tender and swollen joints using a 28-joint count, Physician's Global Assessment of Disease Activity using a visual analog scale (VAS) where 0=no activity at all and 100=worst activity imaginable, Patient's Global Assessment of Disease Activity using a VAS where 0=no arthritis activity at all and 100=worst arthritis activity imaginable, and C-reactive protein (CRP) in mg/dL. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. SDAI remission was defined as a score of ≤ 3.3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"92.1","spread":null},{"groupId":"OG002","value":"96.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"64.0","spread":null},{"groupId":"OG002","value":"74.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.8","spread":null},{"groupId":"OG001","value":"56.6","spread":null},{"groupId":"OG002","value":"62.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","spread":null},{"groupId":"OG001","value":"55.6","spread":null},{"groupId":"OG002","value":"55.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.5","spread":null},{"groupId":"OG001","value":"52.1","spread":null},{"groupId":"OG002","value":"56.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Boolean Remission at All Measured Timepoints","description":"A participant achieves Boolean remission (66/68-joint count) if all of the following criteria are met at a single timepoint:\n\n* 68-joint tender joint count ≤ 1\n* 66-joint swollen joint count ≤ 1\n* CRP (mg/dL) ≤ 1\n* Patient's Global Assessment of Disease Activity using a VAS (where 0=no arthritis activity at all and 10=worst arthritis activity imaginable) ≤ 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.0","spread":null},{"groupId":"OG001","value":"34.7","spread":null},{"groupId":"OG002","value":"45.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"23.0","spread":null},{"groupId":"OG002","value":"19.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"26.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":null},{"groupId":"OG001","value":"20.4","spread":null},{"groupId":"OG002","value":"27.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":null},{"groupId":"OG001","value":"13.3","spread":null},{"groupId":"OG002","value":"25.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Worsening","description":"Percentage of participants who fulfilled disease-worsening criteria for the first time is presented. Disease worsening is defined as any of the following:\n\n* an SDAI \\> 3.3 and ≤ 11 during 2 consecutive visits at least 2 weeks apart\n* SDAI \\> 3.3 and ≤ 11 on 3 or more separate visits\n* SDAI \\> 11 after randomization.\n\nThe SDAI is a composite score that is based on the number of tender and swollen joints using a 28-joint count, Physician's Global Assessment of Disease Activity using a visual analog scale (VAS) where 0=no activity at all and 100=worst activity imaginable, Patient's Global Assessment of Disease Activity using a VAS where 0=no arthritis activity at all and 100=worst arthritis activity imaginable, and C-reactive protein (CRP) in mg/dL. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. SDAI remission was defined as a score of ≤ 3.3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","spread":null},{"groupId":"OG001","value":"23.0","spread":null},{"groupId":"OG002","value":"17.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":null},{"groupId":"OG001","value":"14.6","spread":null},{"groupId":"OG002","value":"6.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":null},{"groupId":"OG001","value":"3.2","spread":null},{"groupId":"OG002","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"4.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Disease Worsening","description":"Disease worsening is defined as any of the following:\n\n* an SDAI \\> 3.3 and ≤ 11 during 2 consecutive visits at least 2 weeks apart\n* SDAI \\> 3.3 and ≤ 11 on 3 or more separate visits\n* SDAI \\> 11 after randomization.\n\nThe SDAI is a composite score that is based on the number of tender and swollen joints using a 28-joint count, Physician's Global Assessment of Disease Activity using a visual analog scale (VAS) where 0=no activity at all and 100=worst activity imaginable, Patient's Global Assessment of Disease Activity using a VAS where 0=no arthritis activity at all and 100=worst arthritis activity imaginable, and C-reactive protein (CRP) in mg/dL. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. SDAI remission was defined as a score of ≤ 3.3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.14","spread":null},{"groupId":"OG001","value":"13.21","spread":null},{"groupId":"OG002","value":"18.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Recapture SDAI Remission After Starting Rescue Treatment","description":"In participants who receive rescue treatment during the double-blind treatment period.\n\nThe SDAI is a composite score that is based on the number of tender and swollen joints using a 28-joint count, Physician's Global Assessment of Disease Activity using a visual analog scale (VAS) where 0=no activity at all and 100=worst activity imaginable, Patient's Global Assessment of Disease Activity using a VAS where 0=no arthritis activity at all and 100=worst arthritis activity imaginable, and C-reactive protein (CRP) in mg/dL. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. SDAI remission was defined as a score of ≤ 3.3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.00","spread":null},{"groupId":"OG001","value":"12.00","spread":null},{"groupId":"OG002","value":"11.36","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Receiving Rescue Treatment Who Experienced SDAI Remission at Week 48","description":"The SDAI is a composite score that is based on the number of tender and swollen joints using a 28-joint count, Physician's Global Assessment of Disease Activity using a visual analog scale (VAS) where 0=no activity at all and 100=worst activity imaginable, Patient's Global Assessment of Disease Activity using a VAS where 0=no arthritis activity at all and 100=worst arthritis activity imaginable, and C-reactive protein (CRP) in mg/dL. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. SDAI remission was defined as a score of ≤ 3.3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.2","spread":null},{"groupId":"OG001","value":"55.9","spread":null},{"groupId":"OG002","value":"66.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":368},"commonTop":["Upper respiratory tract infection","Rheumatoid arthritis","Bronchitis"]}}}